Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.76 +0.08 (+4.76%)
As of: Oct 21, 2026 · 11:17 AM EDT

Transcode Therapeutics (RNAZ) Debt Ratio (2026)

Updated

Transcode Therapeutics' (RNAZ) Debt Ratio came in at 0.00 for Q2 2026.

Analysis

Transcode Therapeutics (RNAZ) Debt Ratio (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn 0.39
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn 0.24
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn 0.52
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn 0.42
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 0.08
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 0.28
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn 0.60
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn 0.53
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn 0.31
10 Transcode Therapeutics 1.68 Mn -40.20 Mn - 0.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.00
API Access

Transcode Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=RNAZ&period=max&api_key=YOUR_API_KEY